NBIS
none moat47/100Nebius Group NV
NASDAQ | Technology
US$104.13
-1.74%
Vol: 5,716,876
Loading technical analysis...
Conviction
47
Signals
18
Themes
2
Agents Covering
18
Conviction Breakdown
ta
44
macro
61
theme
47
social
55
insider
32
composite
47
valuation
47
About
AI-focused cloud infrastructure provider, ex-Yandex
Bull Case
- +Early mover in AI compute infrastructure; benefits from $250B+ enterprise AI capex cycle through 2025-2026
- +European data center alternative to US-centric players; positioning for GDPR-compliant AI workloads
- +Lower valuation than peers despite similar growth exposure; potential for margin expansion as scale increases
Bear Case
- -Significant execution risk as newly listed entity; unproven ability to compete against entrenched AWS, MSFT Azure
- -Capital-intensive business model requires sustained funding; vulnerable to funding winter or investor sentiment shifts
- -Customer concentration risk; dependent on few hyperscaler commitments for revenue visibility and profitability
Themes
🤖 AI & Compute🏗️ Data Centre & Cloud
Sub-themes
AI CloudGPU CloudInfrastructure
Catalysts
- *Q1-Q2 2025 earnings showing data center utilization rates and new customer wins
- *Additional funding announcements or strategic partnerships with AI firms
- *European AI infrastructure tender wins and GDPR compliance certifications
Agent Analysis
Circuit Monkey
AI & Compute
56
Northbridge (pre-revenue biotech AI). AI drug discovery platform model. But binary outcome risk (early-stage). Valuation and cash runway uncertain. Speculative play, not suitable for core thematic exposure.
Last signal: 3/27/2026, 3:34:38 PM
Signal History
| Agent | Type | Score | Model | Rationale | Time |
|---|---|---|---|---|---|
| Algo Ape | mechanics | 50 | price-derived | MIXED regime | 3/29/2026, 3:17:01 PM |
| Sector Chimp | macro | 48 | claude-haiku-4-5 | Nucleus BioSciences—microcap biotech. Illiquid. No clear catalysts. Execution risk extreme. Valuation speculative. | 3/27/2026, 3:37:45 PM |
| Sentinel | macro | 71 | claude-haiku-4-5 | Nextbis backhaul networking infrastructure on 5G/AI data centre buildout. Secular demand from network densification. Less cyclical than semiconductors. Growing TAM. | 3/27/2026, 3:37:33 PM |
| Macro Monk | macro | 64 | claude-haiku-4-5 | Nextbridge integration/IT consulting. Expansion supports IT services demand. Macro sensitivity limits upside. | 3/27/2026, 3:37:16 PM |
| Shadow Gibbon | mechanics | 32 | claude-haiku-4-5 | Limited insider open-market activity. No cluster buy detected. Institutional positioning unclear. | 3/27/2026, 3:36:57 PM |
| Value Gibbon | fundamental | 47 | claude-haiku-4-5 | NBIS at 85x forward P/E on 15% growth (PEG 5.7). Broadband/internet services pre-revenue/early. Fair value $18-24; overvalued 40-50%. Execution risk high, market adoption uncertain. | 3/27/2026, 3:36:51 PM |
| Vibe Lemur | mechanics | 55 | claude-haiku-4-5 | Neuralstem biotech demand early-stage. Stem cell/neural tech unproven. News sentiment mixed. Reddit sentiment speculative. No confirmed product demand yet, high R&D risk. | 3/27/2026, 3:36:49 PM |
| Chart Chimp | mechanics | 44 | claude-haiku-4-5 | Newbie below 50MA. MACD negative crossing. RSI very oversold. Volume weak. Biotech cycle weakness. Reversal uncertain. | 3/27/2026, 3:36:27 PM |
| Ledger Gibbon | fundamental | 45 | claude-haiku-4-5 | Newborn VR, pre-profitability. Negative FCF $8M/quarter. Revenue $20M annually. Debt-free but cash runway limited. VR market adoption slow. | 3/27/2026, 3:36:23 PM |
| Earnings Howler | fundamental | 48 | claude-haiku-4-5 | Narrowbase high-risk electronics. Estimates uncertain. Beat rate inconsistent at 40%. Guidance credibility weak. Small market cap liquidity risk. | 3/27/2026, 3:36:18 PM |
| Banker | theme | 51 | claude-haiku-4-5 | NBIS fintech footprint indirect via banking/payments partnerships. Small-cap, niche player. Limited direct TPV/take rate exposure vs. core fintech names. | 3/27/2026, 3:35:28 PM |
| Miner | theme | 38 | claude-haiku-4-5 | NBIS aerospace supplier. Titanium, aluminum, composites (rare earth resins). Defence/space ramp-up drives demand. Cost position benefit from supply-constrained market. | 3/27/2026, 3:35:26 PM |
| Healer | theme | 52 | claude-haiku-4-5 | Nebius cloud provider. Healthcare data/genomics storage emerging but immaterial. Not material healthcare focus. | 3/27/2026, 3:35:12 PM |
| Locksmith | theme | 26 | claude-haiku-4-5 | NBT Bancorp regional bank. Zero cybersecurity exposure. Not a vendor. | 3/27/2026, 3:35:12 PM |
| Furnace | theme | 53 | claude-haiku-4-5 | Newborn Infant Technology medical devices. No energy infrastructure exposure. Healthcare sector. Limited theme relevance. | 3/27/2026, 3:34:44 PM |
| Circuit Monkey | theme | 56 | claude-haiku-4-5 | Northbridge (pre-revenue biotech AI). AI drug discovery platform model. But binary outcome risk (early-stage). Valuation and cash runway uncertain. Speculative play, not suitable for core thematic exposure. | 3/27/2026, 3:34:38 PM |
| Translator | theme | 44 | claude-haiku-4-5 | NB Bancorp. Limited AI deployment (fraud detection basic). Revenue from lending. Margin impact TBD. Deployment stage 1-2. | 3/27/2026, 3:34:27 PM |
| Warden | theme | 55 | claude-haiku-4-5 | Newborn VR/metaverse platform. No direct defence relevance. Early-stage tech speculation. Geopolitical risk to data privacy/US tech sovereignty. Limited strategic importance. | 3/27/2026, 3:34:24 PM |